


IN THE CLAIMS:

This listing of claims will replace all prior versions and listing of claims in the application.

Listing of claims:

Claim 1 (currently amended): A compound of formula (I):

**(I)**

wherein:

R¹ is halo, cyano, C₁₋₃alkyl or C₁₋₃alkoxy;

p is 0-2; wherein the values of R¹ may be the same or different;

R² is hydrogen, C₁₋₄alkyl, C₂₋₄alkenyl, C₂₋₄alkynyl, C₃₋₆cycloalkyl, C₃₋₆cycloalkylC₁₋₃alkyl, a heterocyclyl or heterocyclylC₁₋₃alkyl; wherein R² may be optionally substituted on carbon by one or more methyl, ethyl, methoxy, ethoxy, propoxy, trifluoromethyl, trifluoromethoxy, 2,2,2-trifluoroethoxy or cyclopropylmethoxy; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by one or more methyl, ethyl, acetyl, 2,2,2-trifluoroethyl or methoxyethyl;

R³ is hydrogen, halo or cyano;

R⁴ is C₂₋₆alkyl-C₁₋₆alkyl or C₁₋₆alkoxyC₁₋₆alkyl;

R⁵ is C₁₋₆alkyl or C₂₋₆alkenyl; wherein R⁵ may be optionally substituted on carbon by one or more methoxy, ethoxy, propoxy, trifluoromethyl, trifluoromethoxy, 2,2,2-trifluoroethoxy or cyclopropylmethoxy;

R⁶ is halo or C₁₋₄alkyl;

or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof;

~~with the proviso that if R⁴, R⁵ and R⁶ are all methyl then R² is not hydrogen, optionally substituted C₁₋₄alkyl or C₃₋₆cycloalkyl.~~

Claim 2 (**currently amended**): The A-compound of formula (I) according to claim 1 wherein p is 0; or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.

Claim 3 (**currently amended**): The A-compound of formula (I) according to claim 1 ~~or 2~~ wherein R² is hydrogen; or C₁₋₄alkyl or heterocyclylC₁₋₃alkyl; wherein R² may be optionally substituted on carbon by one or more methoxy or ethoxy; or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.

Claim 4 (**currently amended**): The A-compound of formula (I) according to claim 1 ~~anyone of claims 1-3~~ wherein R³ is hydrogen ~~or halo~~; or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.

Claim 5 (**currently amended**): The A-compound of formula (I) according to claim 1 ~~anyone of claims 1-4~~ wherein R⁴ is C₂₋₄alkyl-C₁₋₄alkyl; or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.

Claim 6 (**currently amended**): The A-compound of formula (I) according to claim 1 ~~anyone of claims 1-5~~ wherein R⁵ is C₁₋₆alkyl; or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.

Claim 7 (**currently amended**): The A-compound of formula (I) according to claim 1 ~~anyone of claims 1-6~~ wherein R⁶ is methyl ~~or halo~~; or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.

Claim 8 (**currently amended**): The A-compound of formula (I) according to claim 1 ~~(as depicted in claim 1)~~ wherein:

p is 0;

R^2 is hydrogen, 2-methoxyethyl, methyl, 3-methoxypropyl or 2-ethoxyethyl ~~or 2-pyrazol-1-ylethyl~~;

R^3 is hydrogen ~~or bromo~~;

R^4 is ~~methyl~~, ethyl or isopropyl;

R^5 is methyl or ethyl;

R^6 is methyl ~~or bromo~~;

or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof;

~~with the proviso that if R^4 , R^5 and R^6 are all methyl then R^2 is not hydrogen, 2-methoxyethyl, methyl, 3-methoxypropyl or 2-ethoxyethyl.~~

Claim 9 (currently amended): The A-compound of formula (I) according to claim 1
(~~as depicted in claim 1~~) selected from:

4-(1,2-diethyl-4-methylimidazol-5-yl)-2-{4-[N-(2-methoxyethyl)sulphamoyl]anilino}
pyrimidine;

4-(1-ethyl-2,4-dimethylimidazol-5-yl)-2-{4-[N-(2-ethoxyethyl)sulphamoyl]anilino}
pyrimidine;

4-(1-ethyl-2,4-dimethylimidazol-5-yl)-2-{4-[N-(3-methoxypropyl)sulphamoyl]anilino}
pyrimidine;

4-(1-ethyl-2,4-dimethylimidazol-5-yl)-2-{4-[N-(2-methoxyethyl)sulphamoyl]anilino}
pyrimidine;

4-(1-ethyl-2,4-dimethylimidazol-5-yl)-2-{4-[N-(methyl)sulphamoyl]anilino}pyrimidine;

4-(1-ethyl-2,4-dimethylimidazol-5-yl)-2-(4-sulphamoylanilino)pyrimidine;

4-(1-isopropyl-2,4-dimethylimidazol-5-yl)-2-{4-[N-(2-methoxyethyl)sulphamoyl]anilino}
pyrimidine;

4-(1-isopropyl-2,4-dimethylimidazol-5-yl)-2-{4-[N-(3-methoxypropyl)sulphamoyl]anilino}
pyrimidine;

4-(1-isopropyl-2,4-dimethylimidazol-5-yl)-2-(4-sulphamoylanilino)pyrimidine;

4-(1-isopropyl-2,4-dimethylimidazol-5-yl)-2-{4-[N-(2-ethoxyethyl)sulphamoyl]anilino}

pyrimidine; or

4-(1-isopropyl-2,4-dimethylimidazol-5-yl)-2-{4-[N-(methyl)sulphamoyl]anilino} pyrimidine;

4-(1,2,4-trimethylimidazol-5-yl)-2-{4-[N-(2-pyrazol-1-ylethyl)sulphamoyl]anilino}

pyrimidine; or


4-(4-bromo-1,2-dimethylimidazol-5-yl)-2-{4-[N-(2-methoxyethyl)sulphamoyl]anilino}

pyrimidine;

or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.


Claim 10 (**currently amended**): A process for preparing a compound of formula (I) or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof as claimed in claim 1, which process (wherein R¹, R², R³, R⁴, R⁵, R⁶ and p are, unless otherwise specified, as defined in claim 1) comprises of:

Process a) reaction of a pyrimidine of formula (II):



(II)


wherein L is a displaceable group; with an aniline of formula (III):



(III)


or

Process b) reacting a compound of formula (IV):



(IV)


with a compound of formula (V):



(V)


wherein T is O or S; R^x may be the same or different and is C_{1-6} alkyl;

Process c) reacting a pyrimidine of formula (VI):



(VI)


wherein X is a displaceable group; with an amine of formula (VII):



(VII)


or

Process d) reacting a pyrimidine of formula (VIII)



(VIII)

with a compound of formula (IX):



(IX)

where Y is a displaceable group;

and thereafter, optionally if necessary:

- i) converting a compound of the formula (I) into another compound of the formula (I);
- ii) removing any protecting groups;
- iii) forming a pharmaceutically acceptable salt or *in vivo* hydrolysable ester.

Claim 11 (**currently amended**): A pharmaceutical composition which comprises a compound of the formula (I), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, according to claim 1 ~~any one of claims 1-9~~, in association with a pharmaceutically-acceptable diluent or carrier.

Claim 12-21 (**cancelled**).

Claim 22 (**new**): A method for producing a cell cycle inhibitory (anti-cell-proliferation) effect in a warm-blooded animal in need of such treatment, which comprises administering to said animal an effective amount of a compound of formula (I) or a

pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof as claimed in claim 1.

Claim 23 (**new**): A method for the inhibition of CDK2, CDK4 or CDK6 in a warm-blooded animal in need thereof, which comprises administering to said animal an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or *in-vivo* hydrolysable ester thereof as claimed in claim 1.

Claim 24 (**new**): A method of treating cancer in a warm-blooded animal in need thereof, which comprises administering to said animal an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or *in-vivo* hydrolysable ester thereof as claimed in claim 1.

Claim 25 (**new**): The method of claim 24 wherein said cancer is selected from leukaemia, breast cancer, lung cancer, colorectal cancer, stomach cancer, prostate cancer, bladder cancer, pancreatic cancer, ovarian cancer, liver cancer, kidney cancer, skin cancer and cancer of the vulva.